IRIS
PELAIA, CORRADO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 1.963
NA - Nord America 1.878
EU - Europa 1.029
SA - Sud America 828
AF - Africa 62
OC - Oceania 6
Continente sconosciuto - Info sul continente non disponibili 3
Totale 5.769
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.798
SG - Singapore 839
BR - Brasile 654
IT - Italia 521
VN - Vietnam 378
CN - Cina 319
IN - India 205
DE - Germania 162
AR - Argentina 79
FI - Finlandia 76
HK - Hong Kong 68
GB - Regno Unito 67
CA - Canada 41
SE - Svezia 40
ID - Indonesia 39
EC - Ecuador 34
BD - Bangladesh 31
NL - Olanda 28
MX - Messico 27
RU - Federazione Russa 23
ZA - Sudafrica 20
ES - Italia 19
UA - Ucraina 18
CO - Colombia 17
EG - Egitto 15
FR - Francia 14
IQ - Iraq 14
PY - Paraguay 14
PE - Perù 12
PL - Polonia 12
AT - Austria 11
CZ - Repubblica Ceca 10
MA - Marocco 10
JP - Giappone 9
CL - Cile 8
TR - Turchia 7
IE - Irlanda 6
MY - Malesia 6
SA - Arabia Saudita 6
TW - Taiwan 6
AU - Australia 5
DO - Repubblica Dominicana 5
UY - Uruguay 5
VE - Venezuela 5
EE - Estonia 4
KE - Kenya 4
TN - Tunisia 4
UZ - Uzbekistan 4
AE - Emirati Arabi Uniti 3
ET - Etiopia 3
IL - Israele 3
IR - Iran 3
KR - Corea 3
KZ - Kazakistan 3
LT - Lituania 3
PH - Filippine 3
PK - Pakistan 3
PT - Portogallo 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
GR - Grecia 2
JO - Giordania 2
RO - Romania 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
AL - Albania 1
AZ - Azerbaigian 1
BB - Barbados 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CG - Congo 1
CI - Costa d'Avorio 1
CR - Costa Rica 1
CY - Cipro 1
DZ - Algeria 1
EU - Europa 1
HU - Ungheria 1
JM - Giamaica 1
KI - Kiribati 1
LB - Libano 1
LV - Lettonia 1
MR - Mauritania 1
NE - Niger 1
NG - Nigeria 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
SI - Slovenia 1
SV - El Salvador 1
Totale 5.769
Salva come PNG Salva come JPEG
Città #
Dallas 370
Singapore 345
Santa Clara 175
Chandler 170
Ho Chi Minh City 166
Bengaluru 164
Hefei 159
Munich 106
Ashburn 91
Hanoi 70
Milan 68
Hong Kong 66
Princeton 66
Lawrence 65
São Paulo 56
Turku 53
Chicago 46
Beijing 43
Catanzaro 42
London 41
Wilmington 41
Boardman 33
Los Angeles 30
Naples 27
Rome 24
Haiphong 23
Palermo 22
Helsinki 20
Rio de Janeiro 19
San Nicola Manfredi 18
Des Moines 16
Thái Bình 16
Florence 15
Biên Hòa 14
Johannesburg 14
Ninh Bình 14
Quito 14
San Francisco 14
Bari 13
Guayaquil 13
Brasília 12
Brooklyn 12
Buenos Aires 11
New York 11
Porto Alegre 11
Redwood City 11
Troina 11
Warsaw 11
Belo Horizonte 10
Olomouc 10
Curitiba 9
Lima 9
Mexico City 9
Norwalk 9
Atlanta 8
Galbiate 8
Montreal 8
Ottawa 8
Redmond 8
Salvador 8
Alessandria 7
Amsterdam 7
Baghdad 7
Guarulhos 7
Hải Dương 7
Messina 7
Seattle 7
Tokyo 7
Asunción 6
Boston 6
Can Tho 6
Castrovillari 6
Denver 6
Manaus 6
Phoenix 6
Stockholm 6
São Bernardo do Campo 6
São Luís 6
The Dalles 6
Toronto 6
Ankara 5
Aracaju 5
Bauru 5
Bogotá 5
Bắc Giang 5
Caxias do Sul 5
Cosenza 5
Da Nang 5
Dublin 5
Hanover 5
Lamezia Terme 5
Osasco 5
Padova 5
Ribeirão Preto 5
Santo André 5
Sorocaba 5
Taipei 5
Thái Nguyên 5
Uberlândia 5
Ahmedabad 4
Totale 3.183
Salva come PNG Salva come JPEG
Nome #
Patient-derived 3D nasal spheroids reveal epithelial changes following Dupilumab therapy in CRSwNP: a preliminary report 136
25-Hydroxy Vitamin D Detection Using Different Analytic Methods in Patients with Migraine 105
Arg16Gly 132-Adrenoreceptor Polymorphism in Severe Eosinophilic Asthma: Implications for Mepolizumab Long-Term Effectiveness and Clinical Remission 86
An Analytical Method for Assessing Optimal Storage Conditions of Gingival Crevicular Fluid and Disclosing a Peptide Biomarker Signature of Gingivitis by MALDI-TOF MS 80
Benralizumab Effectiveness in Severe Eosinophilic Asthma with and without Chronic Rhinosinusitis with Nasal Polyps: A Real-World Multicenter Study 73
Uric acid and vascular damage in essential hypertension: Role of insulin resistance 69
Benralizumab: From the basic mechanism of action to the potential use in the biological therapy of severe eosinophilic asthma 66
Biological mechanisms underlying the clinical effects of allergen-specific immunotherapy in asthmatic children 62
Evaluation of a New Interface Combining High-Flow Nasal Cannula and CPAP 61
Rapid detection and identification of antimicrobial peptide fingerprints of nasal fluid by mesoporous silica particles and MALDI-TOF/TOF mass spectrometry: from the analytical approach to the diagnostic applicability in precision medicine 61
High-flow nasal cannula oxygen therapy for outpatients undergoing flexible bronchoscopy: a randomised controlled trial 61
Effects of the first three doses of benralizumab on symptom control, lung function, blood eosinophils, oral corticosteroid intake, and nasal polyps in a patient with severe allergic asthma 59
New treatments for asthma: From the pathogenic role of prostaglandin D2 to the therapeutic effects of fevipiprant 56
Type 2 severe asthma: pathophysiology and treatment with biologics 55
MALDI MS-Based Investigations Targeting SARS-CoV-2 55
Benralizumab in the treatment of severe asthma: design, development and potential place in therapy 54
Hexagonal Mesoporous Silica as a Rapid, Efficient and Versatile Tool for MALDI-TOF MS Sample Preparation in Clinical Peptidomics Analysis: A Pilot Study. 53
Association Between Sleep Apnea and Valvular Heart Diseases 53
Short term effect of sacubitril/valsartan on comprehensive geriatric assessment in chronic heart failure: a real life analysis 52
Effects of Sacubitril-Valsartan on Clinical, Echocardiographic, and Polygraphic Parameters in Patients Affected by Heart Failure With Reduced Ejection Fraction and Sleep Apnea 50
Long-Term Clinical and Sustained REMIssion in Severe Eosinophilic Asthma Treated With Mepolizumab: The REMI-M Study 50
Nasal polyposis: Insights in epithelial-mesenchymal transition and differentiation of polyp mesenchymal stem cells 49
Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose 48
Recognizing, quantifying and managing patient-ventilator asynchrony in invasive and noninvasive ventilation. 47
Comparisons of two diaphragm ultrasound-teaching programs: a multicenter randomized controlled educational study. 47
Biologics in severe asthma 47
Eosinophilic inflammation: An Appealing Target for Pharmacologic Treatments in Severe Asthma 46
Cluster Analysis Identifies Patients With Severe Eosinophilic Asthma Who Achieve Super-Response and Remission With Mepolizumab 46
Association between right ventricular dysfunction and adverse cardiac events in mild COPD patients 46
Clinical remission in severe asthma: lights and shadows on an ambitious goal 46
Fluid Challenge During Anesthesia: A Systematic Review and Meta-analysis. 46
Current Practice of High Flow through Nasal Cannula in Exacerbated COPD Patients 46
Emerging biological treatments for asthma 45
Device for Performing Spirometry in Total Laryngectomized Patients 44
Basophil activation test for Staphylococcus aureus enterotoxins in severe asthmatic patients 44
Spotlight on a Short-Time Treatment with the IL-4/IL-13 Receptor Blocker in Patients with CRSwNP: microRNAs Modulations and Preliminary Clinical Evidence 44
Real-World Evaluation of Dupilumab in the Long-Term Management of Eosinophilic Chronic Rhinosinusitis with Nasal Polyps: A Focus on IL-4 and IL-13 Receptor Blockade 43
Assessment of cephalometric parameters and correlation with the severity of the obstructive sleep apnea syndrome 43
Switching Biological Therapies in Severe Asthma 43
Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub-phenotypes of response identified by cluster analysis 43
Neuron-specific enolase serum levels in COVID-19 are related to the severity of lung injury 43
Nurse led protocols for control of glycaemia in critically ill patients: A systematic review 42
Gingival Crevicular Fluid Peptidome Profiling in Healthy and in Periodontal Diseases. 42
Oxygenation strategies during flexible bronchoscopy: a review of the literature 42
Asthma control during COVID-19 lockdown in patients with severe asthma under biological drug treatment 42
Patient-ventilator asynchrony in adult critically ill patients 42
Benefits of secretion clearance with high frequency percussive ventilation in tracheostomized critically ill patients: a pilot study 41
Clinical relevance of understanding mitogen-activated protein kinases involved in asthma 41
Oxygen therapy via high flow nasal cannula in severe respiratory failure caused by Sars-Cov-2 infection: a real-life observational study 41
Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study 41
Real-Life Clinical and Functional Effects of Fluticasone Furoate/Umeclidinium/Vilanterol-Combined Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease 41
Pathobiology of Type 2 Inflammation in Asthma and Nasal Polyposis 40
Allergy clinics in times of the SARS-CoV-2 pandemic: An integrated model 40
An integrated metabo-lipidomics profile of induced sputum for the identification of novel biomarkers in the differential diagnosis of asthma and COPD 40
Phenotyping severe asthma: a rationale for biologic therapy 40
Tezepelumab: A potential new biological therapy for severe refractory asthma 40
Clinical and economic consequences of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma 40
Biological Therapy of Severe Asthma with Dupilumab, a Dual Receptor Antagonist of Interleukins 4 and 13 39
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis 39
Mapping the SARS-CoV-2–host protein–protein interactome by affinity purification mass spectrometry and proximity-dependent biotin labeling: A rational and straightforward route to discover host-directed anti-SARS-CoV-2 therapeutics 39
Switch from omalizumab to benralizumab in allergic patients with severe eosinophilic asthma: A real-life experience from Southern Italy 39
Severe Asthma Remissions Induced by Biologics Targeting IL5/IL5r: Results from a Multicenter Real-Life Study 38
Imaging of chronic rhinosinusitis with nasal polyps in the era of biological therapies 38
Switching from omalizumab to mepolizumab: real-life experience from Southern Italy 38
Real-life evaluation of mepolizumab efficacy in patients with severe eosinophilic asthma, according to atopic trait and allergic phenotype 38
Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence. 38
Are Bronchiectasis (BE) Properly Investigated in Patients with Severe Asthma? A Real-Life Report from 8 Italian Centers 38
Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational study 38
Can Leukotriene Receptor Antagonist Therapy Improve the Control of Patients with Severe Asthma on Biological Therapy and Coexisting Bronchiectasis? A Pilot Study 37
Influence of allergic status and nasal polyposis on long-term Benralizumab response in eosinophilic severe asthma 37
Effect of Statins on Lung Cancer Molecular Pathways: A Possible Therapeutic Role 37
Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma 37
What is the Role of Sex-Related Differences in the Effectiveness and Safety of Biological Drugs used in Patients' Severe Asthma? 36
Long-term treatment in pediatric asthma: an update on chemical pharmacotherapy 36
Biologicals reduce drug burden and improve physical and mental health in severe eosinophilic asthma 36
Mepolizumab effectiveness on small airway obstruction, corticosteroid sparing and maintenance therapy step-down in real life 36
Interleukin-5 in the Pathophysiology of Severe Asthma 36
Adherence to omalizumab: A multicenter “real-world” study 36
Effect of continuous positive airway pressure on non-fatal stroke and paroxysmal atrial fibrillation recurrence in obstructive sleep apnoea elderly patients 36
New Onset of Eosinophilic Granulomatosis with Polyangiitis Following mRNA-Based COVID-19 Vaccine 35
Clinical and Functional Effects of Inhaled Dual Therapy Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease: A Real-Life Study 35
Effects of continuous positive airway pressure on comprehensive geriatric assessment and cognitive function in elderly patients with obstructive sleep apnea syndrome 35
Real-Life Effects of Omalizumab on Chronic Rhinosinusitis with Nasal Polyposis 35
Omalizumab, the first available antibody for biological treatment of severe asthma: more than a decade of real-life effectiveness 35
Intrinsic laryngeal lipoma treated with transoral Co2 laser microsurgery: An unusual case report 35
Real-life effectiveness of mepolizumab on forced expiratory flow between 25% and 75% of forced vital capacity in patients with severe eosinophilic asthma 35
Predictors of renal function worsening in patients with chronic obstructive pulmonary disease (Copd): A multicenter observational study 35
Extended nitric oxide analysis in patients with chronic rhinosinusitis with nasal polyps, with or without associated asthma 34
Tissue microRNA dynamics in sinonasal inverted papilloma: implications for pathology and therapy 34
Sustained remission induced by 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and nasal polyposis 34
Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma 34
Therapeutic effects of benralizumab assessed in patients with severe eosinophilic asthma: Real-life evaluation correlated with allergic and non-allergic phenotype expression 34
Effectiveness of Benralizumab in OCS-Dependent Severe Asthma: The Impact of 2 Years of Therapy in a Real-Life Setting 33
Primary mucosal melanoma presenting with a unilateral nasal obstruction of the left inferior turbinate 33
Is Bronchiectasis (BE) Properly Investigated in Patients with Severe Asthma? A Real-Life Report from Eight Italian Centers 32
Effectiveness of mepolizumab in a real-life cohort of patients with severe refractory eosinophilic asthma and multiple comorbidities 32
Complications during Veno-Venous Extracorporeal Membrane Oxygenation in COVID-19 and Non-COVID-19 Patients with Acute Respiratory Distress Syndrome 32
Effectiveness and safety of anti-IL-5/Rα biologics in eosinophilic granulomatosis with polyangiitis: a two-year multicenter observational study 31
Interleukin 33: a suitable target for biological therapies of COPD? 31
Pre-biologic FeNO might predict anti-IL-5/IL-5Rα response to treatment in severe asthmatics 31
Totale 4.485
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.003
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 53.003
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021123 0 0 0 0 22 13 3 9 57 10 5 4
2021/2022233 5 5 29 31 7 8 22 40 29 22 34 1
2022/2023600 137 32 40 23 60 52 26 51 80 27 52 20
2023/2024380 67 45 32 27 12 75 6 17 6 25 24 44
2024/20251.637 166 18 26 32 191 215 109 49 165 53 257 356
2025/20262.949 237 492 774 1.013 433 0 0 0 0 0 0 0
Totale 6.000